000177084 001__ 177084
000177084 005__ 20240229133731.0
000177084 0247_ $$2pmid$$apmid:34661927
000177084 0247_ $$2ISSN$$a0926-9959
000177084 0247_ $$2ISSN$$a1468-3083
000177084 0247_ $$2doi$$adoi: 10.1111/jdv.17744
000177084 0247_ $$2altmetric$$aaltmetric:115409317
000177084 037__ $$aDKFZ-2021-02290
000177084 041__ $$aEnglish
000177084 082__ $$a610
000177084 1001_ $$aGambichler, Thilo$$b0
000177084 245__ $$aCutaneous findings following COVID-19 vaccination: Review of world literature and own experience.
000177084 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2022
000177084 3367_ $$2DRIVER$$aarticle
000177084 3367_ $$2DataCite$$aOutput Types/Journal article
000177084 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642494051_16197$$xReview Article
000177084 3367_ $$2BibTeX$$aARTICLE
000177084 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177084 3367_ $$00$$2EndNote$$aJournal Article
000177084 500__ $$a2022 Feb;36(2):172-180
000177084 520__ $$aThere is growing evidence that not only the novel coronavirus disease (COVID-19) but also the COVID-19 vaccines can cause a variety of skin reactions. In this review article, we provide a brief overview on cutaneous findings that have been observed since the emerging mass COVID-19 vaccination campaigns all over the world. Unspecific injection site reactions very early occurring after the vaccination are most frequent. Type I hypersensitivity reactions (e.g., urticaria, angioedema, anaphylaxis) likely due to allergy to ingredients may rarely occur but can be severe. Type IV hypersensitivity reactions may be observed, including delayed large local skin lesions ('COVID arm'), inflammatory reactions in dermal filler or previous radiation sites or even old BCG scars, and more commonly moribilliform and erythema multiforme-like rashes. Autoimmune-mediated skin findings after COVID-19 vaccination include leukocytoclastic vasculitis, lupus erythematosus, and immune thrombocytopenia. Functional angiopathies (chilblain-like lesions, erythromelalgia) may also be observed. Pityriasis rosea-like rashes and reactivation of herpes zoster have also been reported after COVID-19 vaccination. In conclusion, there are numerous cutaneous reaction patterns that may occur following COVID-19 vaccination, whereby many of these skin findings are of immunological/autoimmunological nature. Importantly, molecular mimicry exists between SARS-CoV-2 (e.g., the spike-protein sequences used to design the vaccines) and human components and may thus explain some COVID-19 pathologies as well adverse skin reactions to COVID-19 vaccinations.
000177084 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000177084 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177084 650_7 $$2Other$$aCOVID-19
000177084 650_7 $$2Other$$aSARS-CoV-2
000177084 650_7 $$2Other$$aadverse events
000177084 650_7 $$2Other$$acoronavirus
000177084 650_7 $$2Other$$acutaneous reactions
000177084 650_7 $$2Other$$amolecular mimicry
000177084 650_7 $$2Other$$aside-effects
000177084 650_7 $$2Other$$askin
000177084 650_7 $$2Other$$avaccination
000177084 650_7 $$2Other$$avaccine
000177084 7001_ $$aBoms, Stefanie$$b1
000177084 7001_ $$aSusok, Laura$$b2
000177084 7001_ $$aDickel, Heinrich$$b3
000177084 7001_ $$aFinis, Cansu$$b4
000177084 7001_ $$aAbu Rached, Nessr$$b5
000177084 7001_ $$aBarras, Milan$$b6
000177084 7001_ $$aStücker, Markus$$b7
000177084 7001_ $$0P:(DE-He78)a9aa7740c4c6f243d651d9bd35ed7fdf$$aKasakovski, Dimitri$$b8$$eLast author$$udkfz
000177084 773__ $$0PERI:(DE-600)2022088-1$$a10.1111/jdv.17744$$n2$$p172-180$$tJournal of the European Academy of Dermatology and Venereology$$v36$$x0926-9959$$y2022
000177084 909CO $$ooai:inrepo02.dkfz.de:177084$$pVDB
000177084 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9aa7740c4c6f243d651d9bd35ed7fdf$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000177084 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000177084 9141_ $$y2021
000177084 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-26$$wger
000177084 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000177084 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000177084 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000177084 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000177084 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000177084 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000177084 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000177084 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000177084 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ EUR ACAD DERMATOL : 2021$$d2022-11-11
000177084 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000177084 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000177084 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ EUR ACAD DERMATOL : 2021$$d2022-11-11
000177084 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000177084 980__ $$ajournal
000177084 980__ $$aVDB
000177084 980__ $$aI:(DE-He78)A190-20160331
000177084 980__ $$aUNRESTRICTED